Founded in 2008, Biosplice Therapeutics operates in biopharmaceutical — regenerative medicine / alternative pre-mrna splicing therapeutics. Investors last valued the company at $12B. The stock is not listed on any public market.
3 valuations. The latest, $12B post-money, was set by the Series D in Apr 2021.
aMoonLEADFFortuna HoldingsAaMoon FundVVerition Fund ManagementIInter IKEA GroupVVickers Venture PartnersSSymBiosis IIPPlutus Investment Group
Sands CapitalaMoonBiosplice Therapeutics, formerly known as Samumed, is a clinical-stage biopharmaceutical company founded in 2008 and headquartered in San Diego, California. It develops small-molecule therapeutics based on alternative pre-mRNA splicing and Wnt-pathway modulation, with its lead program targeting knee osteoarthritis.
Its most advanced compound, lorecivivint, is an injectable inhibitor of the CLK and DYRK kinase families that has shown improvement in pain, function, and joint structure in trials, and Biosplice submitted a new drug application to the FDA for it in late 2025.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Biosplice Therapeutics.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Biosplice Therapeutics availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Biosplice Therapeutics included.
The closest biopharmaceutical — regenerative medicine / alternative pre-mrna splicing therapeutics peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Biosplice Therapeutics is a private company; its shares do not trade on a public exchange.
The last valuation is $12B.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
